SABCS 2021 Highlights Podcast

In this episode (23:45 minutes), Medicom’s correspondent covers 6 presentations from the San Antonio Breast Cancer Symposium (SABCS 2021), which was held in San Antonio, Texas USA, 07-10 December 2021.

1. Olaparib is well tolerated as an additional adjuvant treatment
   Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. Moreover, patient-reported outcomes suggested that olaparib is not associated with a negative impact on the quality of life of these patients.
2. Breast cancer patients with ER mutations may benefit from early switch to fulvestrant/palbociclib
   Among patients with HR-positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed rising ESR1 mutations before disease progression doubled their median progression-free survival following a switch to fulvestrant plus palbociclib. This result from the phase 3 PADA-1 trial may justify the implementation of the PADA-1 treatment strategy as a valid option in clinical routine.
3. Head-to-head comparison of trastuzumab deruxtecan and trastuzumab emtansine favours the first
   Both trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have shown to improve progression-free survival in patients with HER2-positive, metastatic breast cancer. A head-to-head comparison from the phase 3 DESTINY-Breast03 trial revealed that T-DXd outperformed T-DM1 across relevant subgroups, including patients with brain metastases.
4. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab robustly benefits EFS in patients with early triple-negative breast cancer
   The primary analysis of the KEYNOTE-522 trial shows a significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant chemotherapy versus neoadjuvant chemotherapy alone in patients with early triple-negative breast cancer (TNBC). The preliminary sensitivity and subgroup analyses suggested that the EFS-benefit is consistent across pre-defined subgroups.
5. Elacestrant may improve outcomes for patients whose metastatic breast cancer progressed on prior endocrine therapy
   The first results of the EMERALD trial show that elacestrant, the first oral selective oestrogen receptor degrader, delivers clinical benefits over standard endocrine therapy in patients with ER-positive/HER2-negative metastatic breast cancer who progress on CDK4/6 inhibitor plus endocrine therapy.
6. Neratinib/trastuzumab is clinically active in patients with heavily pre-treated, metastatic, HER2-mutated breast cancer.
   Results from the phase 2 SUMMIT trial show that patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with heavily pre-treated HER2-mutated metastatic triple-negative breast cancer (TNBC) may benefit from treatment with neratinib/trastuzumab(/fulvestrant).

Enjoy listening!

Copyright ©2021 Medicom Medical Publisher



Posted on 10 January 20225 July 2024